Abstract
Human cancer stem cells represent promising tools for new approaches to pathway-targeted drug discovery and preclinical screening. Because of their distinctive capability to recapitulate the development of the original tumors in vivo, the study of human cancer stem cells (CSCs) largely relies on models of xenograft transplantation into immunodeficient mice. In this frame, immunity and microenvironment-related issues need careful consideration. Here we shortly revise present knowledge on xenograft-related aspects of human CSCs studies. © 2010 Elsevier Ltd.
| Original language | English |
|---|---|
| Pages (from-to) | 380-384 |
| Number of pages | 5 |
| Journal | Current Opinion in Pharmacology |
| Volume | 10 |
| DOIs | |
| Publication status | Published - 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Antineoplastic Agents
- Cell Line, Tumor
- Drug Discovery
- Drug Discovery3003 Pharmaceutical Science
- Humans
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Neoplasms, Experimental
- Neoplastic Stem Cells
- Pharmacology
- Xenograft Model Antitumor Assays
Fingerprint
Dive into the research topics of 'New models for cancer research: Human cancer stem cell xenografts'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver